View 2 Images

The Government has issued a response after concerns that some patients with weight-related health problems won't be able to access the new weight loss jab Mounjaro on the NHS .

Tirzepatide - better known as Mounjaro - is a weight loss medicine that makes patients feel fuller for longer and therefore less hungry. It comes in the form of an injection, which is self-administered once a week.

The jab was approved for use in England in 2023 and was initially only available through specialist weight-loss services.

In June, thousands more patients became eligible to get the drug through their GP in an NHS rollout . Currently, patients with a BMI of 40 or higher and multiple obesity-related health problems are eligible.

Labour MP Mohammad Yasin, who represents Bedford

See Full Page